Budesonide at different doses for chronic asthma
Abstract
Background
Inhaled budesonide (BUD) is available in a range of doses for treating chronic asthma.
Objectives
To assess the efficacy and safety of budesonide at different doses in order to establish whether a clinically significant dose response profile exists.
Search methods
A search was carried out for Controlled Clinical Trials using the Cochrane Airways Group trial register.
Selection criteria
Randomised trials in children and adults comparing one dose of budesonide to a second dose in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.
Data collection and analysis
One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager 4.0.4 with MetaView 3.1.
Main results
24 studies met the inclusion for the review (3907 participants). In non‐oral steroid treated, mild to moderately severe asthma, no clinically worthwhile differences in FEV1, morning PEFR, symptom scores or rescue beta2 agonist use were apparent across a dose range of 200‐1600 mcg/d. However, in moderate to severe asthma a significant reduction in the likelihood of trial withdrawal due to asthma exacerbation was apparent when treating patients with BUD 800 mcg/d compared to 200 mcg/d: Relative Risk 3.93 (95% confidence interval, 1.4 to 10.9). This result was weighted largely by a single, large, high quality RCT. In severe asthma significant improvements favouring high dose BUD (1600 mcg/d) over low dose (200 mcg/d) were apparent for FEV1 but not morning PEFR. This finding was based on two large RCTs of good quality. In oral steroid treated asthmatics no dose dependent oral steroid sparing effect was apparent for BUD 1600 mcg/d v 800 or 400 mcg/d. Statistically significant, dose dependent suppression of 24 hour urinary free cortisol excretion and serum cortisol post synthetic ACTH infusion over the dose range 800‐3200 mcg/d was apparent but the clinical significance of these findings is unclear.
Authors' conclusions
Budesonide exhibits a significant dose response effect between low and high dose for improvement in FEV1 in severe asthma and reduction of exacerbations in moderate to severe asthma. No significant dose dependent improvements in FEV1, PEFR or symptoms are evident in non‐oral steroid treated asthmatics with mild to moderate disease. Dose dependent alterations in sensitive measures of hypothalamic‐pituitary‐adrenal function were evident but the clinical significance of these changes is unclear.
PICOs
Plain language summary
Budesonide at different doses for asthma
Budesonide is an inhaled corticosteroid used to treat the inflammation of airways (passages to the lungs) that occurs in asthma. This review presents the effects of budesonide at different doses for people with varying degrees of asthma. In patients with mild‐moderate asthma no important differences were apparent between the lowest dose (200 mcg/d) and the highest dose (1600 mcg/d) for measures of airway opening and symptoms. However, patients with more severe asthma are less likely to experience an acute worsening of their asthma control when a higher dose (1600 mcg/d) is used regularly compared to a lower dose (200 mcg/d). Future research should report results more comprehensively, and should use quality of life questionnaires.
